This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stojanovich, L Articles by Dzjolich, E Search for Related Content PubMed PubMed Citation Articles by Stojanovich, L Articles by Dzjolich, E Social Bookmarking                         What's this?

Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study)

Department of Rheumatology, Clinical and Hospital Center ‘Bezanijska Kosa’, Belgrade, Yugoslavia, ljudmila{at}eunet.yu

R Stojanovich

Institute of Rheumatology, Belgrade University Clinical Center, Belgrade, Yugoslavia

V Kostich

Institute of Neurology, Belgrade University Clinical Center, Belgrade, Yugoslavia

E Dzjolich

Institute of Neurology, Belgrade University Clinical Center, Belgrade, Yugoslavia

Sixty SLE patients with only primary neuropsychiatric manifestations (NP-SLE), (54 female and six male; mean age 44.5) were compared consecutively. Forty-six of the patients (78.3%) were presented with a combination of neuropsychiatricsymptoms. Except for the standard immunosero-logical test, all patients underwent clinical, neurological and psychiatric examination, electro-physiological tests [EEG (electro-encephalography involves recording and analysis of electrical signals generated by the brain), EP (the evoked potentials method involves analysis of a series of electrical signals generated in parts of the nervous system following stimulation of sense organs and peripheral nerves) and EMNG (electro-myo-neography is a method of measurement of electrical activity arising from muscle fibers and peripheral nerves)]. This method presents a valuable tool for assessment of functional state of peripheral nervous systems and muscles)), and neuroimaging (MRI of the brain). Thirty-seven out of 60 patients with NP-SLE (group I) were treated with a low dose of i.v. cyclophosphamide(200 - 400 mg per month). The average daily oral dose of prednisone in these patients was 20.5mg. Group II consisted of 23 patients treated with pridnisone (mean dose 20.5 per day) only or with antimalarials. Patients in the first group showed a considerable clinical and electrophysiological improvement of cerebral function, while there was only a slight or no improvement in the second group. The difference between groups was statistically significant.

Key Words: cytotoxic drugs • electrophysiology • neuropsychiatric lupus • systemic lupus erythematosus

Lupus, Vol. 12, No. 1, 3-7 (2003)
DOI: 10.1191/0961203303lu251oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics Ann Rheum Dis, February 1, 2008; 67(2): 195 - 205. [Abstract] [Full Text] [PDF]

				A T Rowshani, P Remans, A Rozemuller, and P P Tak Cerebral vasculitis as a primary manifestation of systemic lupus erythematosus Ann Rheum Dis, May 1, 2005; 64(5): 784 - 786. [Full Text] [PDF]

				C. Gorman, A. Bhatia, and A. Rahman This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis Rheumatology, March 1, 2005; 44(3): 398 - 401. [Full Text] [PDF]

				G Sanna, M L Bertolaccini, and A Mathieu Central nervous system lupus: a clinical approach to therapy Lupus, December 1, 2003; 12(12): 935 - 942. [Abstract] [PDF]

				G. Sanni and M. A Khamashta Low-dose pulse cyclophosphamide in the treatment of neuropsychiatric lupus Lupus, January 1, 2003; 12(1): 1 - 2. [PDF]